FDA approves Otarmeni, first gene therapy for genetic hearing loss, offered free in the U.S.

Baird's international and global growth funds underperform MSCI benchmarks in Q2 2026.

In Q2 2026, Baird's Chautauqua International Growth Fund returned +10.39%, trailing the MSCI ACWI ex-U.S. Index's +14.49%. Key detractors included Alibaba and Lululemon, while Recruit and ASML contributed positively. The Global Growth Fund also lagge...